|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Factors predicting poor prognosis in ischemic colitis显示文摘瞄准:决定临床、分析、内视镜的因素与有关是化学家大肠炎(IC ) 严厉。方法:85 个病人的一个总数从 1996 年 1 月在回顾的研究被注册到 2004 年 5 月。有 53 女性和 32 男性(年龄 74.6+/-9.4 年,范围 45-89 年) 。病人作为 IC 被诊断。下列变量包括年龄,性别,从到承认的症状的外观的时间的经期,病历,药,凳子频率,临床的症状和症状被分析,验血(血克和基本生物化学的侧面) ,和内视镜的调查结果。病人们在温和 IC 组和严重 IC 组(外科或死亡) 被划分。质的变量用 chi 平方测试被分析,参量的数据用学生的 t (P<0.05 ) 被分析。结果:温和 IC 组 69 个病人被在于(42 女性和 27 男性,平均年龄 74.7+/-12.4 年) 。严重 IC 组由 16 个病人组成(11 女性和 5 男性,平均 73.8+/-12.4 年的年龄) 。因为麦克匪特斯氏疗法(没有外科) 的失败,一个病人死了, 15 个病人经历了外科(6 在内视镜的诊断以后并且 9 在 peroperatory 以后诊断) 。85 个病人(9.6%) 中的八个死了,其它被跟随在上面作为为 9.6+/-3.5 瞬间的门诊病人。人口统计的数据,病历,药和凳子频率在两个组(P>0.05 ) 是类似的。说正经的有病的病人比稍微有病的病人有更少的便血(37.5% 对 86.9% , P = 0.000 ) 。更多的心悸亢进(45.4% 对 10.1% , P = 0.011 ) 并且假腹膜炎的更高的流行签名(75% 对 5.7% , P = 0.000 ) 当腹的疼痛的存在和紧张在二个组之间是类似的时,在严重 IC 组被观察。当承认时,有严重 IC 的二个病人有吃惊。关于分析数据,更严重有病的病人被发现比略微有病的病人有贫血症和血钠过少(37.5% 对 10.1% , P = 0.014 和 46.6% 对 14.9% , P = 0.012,分别地) 。狭窄是那比在稍微有病的病人更经常出现在严重有病的病人的唯一的内视镜的发现(66.6% 对 17.3% , P = 0.017 ) 。结论:能预言 IC 的差的预后是便血,心悸亢进和假腹膜炎,贫血症和血钠过少和狭窄的缺席的因素。 | Ramón A■ón Marta Maia Boscá Vicente Sanchiz Joan Tosca Pedro Almela Cirilo Amorós Adolfo Benages | 2006 | World Journal of Gastroenterology2006，12，30： | 21 |
| 2 | Methotrexate induced sprue-like syndrome显示文摘A 52 year-old male patient diagnosed of ankylosing spon-dylitis presented with an iron deficiency anemia after a ten-month treatment of methotrexate. He did not respond to treatment with oral iron not a proton pump inhibitor and an upper endoscopy was performed. The histological study of the duodenal biopsies showed villus atrophy. After removing the methotrexate, administrating intra-muscular iron and undertaking a gluten-free diet, the histological and analytical alterations progressively resolved. | Marta Maia Boscá Ramon Aón Rosana Villagrasa Nelly Balza Cirilo Amorós Adolfo Benages Empar Mayordomo Juan Ramon Corts | 2008 | World Journal of Gastroenterology2008，14，45： | 0 |
| 3 | Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease显示文摘BACKGROUND In recent years,biological therapies have revolutionized the management of inflammatory bowel disease(IBD);however,they are expensive.The development of biosimilar products has allowed us to reduce healthcare costs and improve patients’access to these treatments.Although various studies support the similarity between infliximab and its biosimilar CT-P13 in terms of efficacy and safety,there are unmet needs regarding research on these agents in the context of IBD.AIM To analyze clinical response rates to CT-P13 and adverse events in IBD patients treated in real-life practice.METHODS An observational,prospective,multicenter study of IBD patients treated with CTP13 in clinical practice who were naïve to biological treatments or failed to respond to other anti-tumor necrosis factor drugs or had switched from infliximab originator was carried out.No diagnostic or follow-up interventions were conducted on patients outside usual clinical practice.The primary endpoints were clinical response rates and number of adverse events.The primary efficacy variable was the proportion of patients who were in clinical remission and/or had a clinical response at 3,6,9,and 12 mo.RESULTS A total of 220 IBD patients treated with CT-P13(Remsima®)were included in the study:87(40%)with ulcerative colitis and 133(60%)with Crohn’s disease.Mean age of the patients was 41.47(SD 15.74)years,and 58%were female.Nineteen(9%)patients started treatment with CT-P13 after switching from infliximab.Of the remaining 201 patients,142(65%)were naïve to biologic agents.At baseline,68.6%(n=138/201)of patients presented with active disease.After 12 mo of treatment,14.8%(n=12/81)presented with active disease,and 64.2%(n=52/81)were in clinical remission without corticosteroids.After 3 mo,75.5%(n=115/152)had a clinical response or achieved clinical remission,which was sustained for 12 mo(85.2%;n=69/81).There was a decrease in specific IBD indices at 3,6,9,and 12 mo(P<0.001).A total of 34 adverse events were reported by 27(12.3%)patients,9(26.5%)of which were serious.CONCLUSION CT-P13 is an effective and safe infliximab biosimilar for the treatment of IBD in real-life practice and may be a valid and attractive alternative for the treatment of IBD. | Jose María Huguet Xavier Cortés Marta Maia Bosca-Watts Marian Aguas Nuria Maroto Lidia Martí Cirilo Amorós Jose María Paredes | 2021 | World Journal of Clinical Cases2021，9，36： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员